RT Journal Article
SR Electronic
T1 Validation of the IMPEDE VTE Score for Prediction of Venous Thromboembolism in Multiple Myeloma: A Retrospective Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.10.20247320
DO 10.1101/2020.12.10.20247320
A1 Fahrettin Covut
A1 Ramsha Ahmed
A1 Sanchit Chawla
A1 Frank Ricaurte
A1 Christy J. Samaras
A1 Faiz Anwer
A1 Alex V. Mejia Garcia
A1 Dana E Angelini
A1 Sandra Mazzoni
A1 Beth Faiman
A1 Jason Valent
A1 Jack Khouri
YR 2020
UL http://medrxiv.org/content/early/2020/12/11/2020.12.10.20247320.abstract
AB Venous thromboembolism (VTE) is highly prevalent in Multiple Myeloma (MM) patients, however a reliable VTE prediction tool in MM remains under study. The IMPEDE VTE score has recently emerged as a novel risk prediction tool for VTE in MM but needs external validation in different cohorts. We conducted a retrospective cohort study to validate this score. We reviewed 839 patients who were newly diagnosed with MM between 2010 and 2015 at Cleveland Clinic and included 575 patients in final analysis. The 6-month cumulative incidence of VTE among all patients was 10.7% (95% CI: 8.2 – 13.2) and the c-statistic of the IMPEDE VTE score to predict VTE within 6 months of treatment start was 0.68 (95% CI: 0.61 – 0.75). The 6-month cumulative incidence of VTE was 5.0% (95% CI: 2.1 – 7.9) in the low risk group, compared to 12.6% (95% CI: 8.9% – 16.4%) and 24.1% (95% CI: 12.2 – 36.1) in the intermediate and high risk groups (p<0.001 for both). In addition, a higher proportion of patients in the VTE cohort had ECOG performance status of ≥2 as compared to the no VTE cohort (33% vs. 16%, p=0.001). Other MM characteristics such as stage, immunoglobulin subtype, and cytogenetics were not found to be predictors of VTE. In summary, we have validated the IMPEDE VTE score in our patient cohort and our findings suggest that it can be utilized as a VTE risk stratification tool in prospective studies looking into investigating VTE prophylaxis strategies in MM patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was not funded by any source.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted according to the Declaration of Helsinki and approved by the institutional review board of Cleveland Clinic.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to data can be granted on request to qualified investigators for appropriate use, in accordance with the institutional policy to protect the confidentiality of patients.